Boston Scientific Co. (NYSE:BSX) Stock Position Lifted by Vontobel Holding Ltd.

Vontobel Holding Ltd. grew its position in shares of Boston Scientific Co. (NYSE:BSX) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 990,738 shares of the medical equipment provider’s stock after buying an additional 26,005 shares during the period. Vontobel Holding Ltd. owned about 0.07% of Boston Scientific worth $57,275,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. FMR LLC raised its position in shares of Boston Scientific by 6.8% during the 3rd quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock worth $6,648,595,000 after purchasing an additional 8,045,263 shares during the period. Vanguard Group Inc. raised its position in shares of Boston Scientific by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider’s stock worth $6,534,969,000 after purchasing an additional 1,525,432 shares during the period. Wellington Management Group LLP raised its position in shares of Boston Scientific by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock worth $2,221,641,000 after purchasing an additional 2,336,348 shares during the period. Geode Capital Management LLC raised its position in shares of Boston Scientific by 1.9% during the 1st quarter. Geode Capital Management LLC now owns 25,329,129 shares of the medical equipment provider’s stock worth $1,263,857,000 after purchasing an additional 473,888 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in shares of Boston Scientific by 7.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 23,393,853 shares of the medical equipment provider’s stock worth $1,082,436,000 after purchasing an additional 1,659,431 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the transaction, the director now owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the transaction, the director now owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 16,351 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $69.30, for a total value of $1,133,124.30. Following the completion of the transaction, the executive vice president now owns 50,638 shares in the company, valued at approximately $3,509,213.40. The disclosure for this sale can be found here. Insiders have sold 50,979 shares of company stock worth $3,418,529 over the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently commented on BSX shares. Royal Bank of Canada raised their target price on Boston Scientific from $67.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Needham & Company LLC raised their target price on Boston Scientific from $60.00 to $71.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. TD Cowen raised their target price on Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research report on Thursday, March 7th. Oppenheimer lifted their price target on Boston Scientific from $58.00 to $68.00 and gave the company a “market perform” rating in a research report on Thursday, February 1st. Finally, Wells Fargo & Company lifted their price target on Boston Scientific from $70.00 to $72.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Two analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.14.

Boston Scientific Stock Performance

Shares of BSX stock opened at $68.50 on Monday. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $69.21. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $100.50 billion, a price-to-earnings ratio of 63.62, a P/E/G ratio of 2.38 and a beta of 0.78. The stock’s fifty day simple moving average is $66.99 and its 200-day simple moving average is $59.42.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The business had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. During the same quarter in the previous year, the company posted $0.45 earnings per share. On average, sell-side analysts predict that Boston Scientific Co. will post 2.25 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.